Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Leukosite licenses MAbs from BTG

Executive Summary

LeukoSite (drugs based on blocking leukocytes) licensed exclusive rights from BTG PLC to certain humanized monoclonal antibodies active against the campath antigen, including campath-1H (LDP-03), which the company will co-develop in a JV with Ilex.
Deal Industry
  • Biotechnology
    • Large Molecule
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register